AbbVie Files 2023 10-K, Details Operational Expenses

TL;DR

**AbbVie's 2023 10-K is out, showing significant R&D and operational costs for the pharma giant.**

AI Summary

AbbVie Inc. filed its 10-K on February 20, 2024, for the fiscal year ended December 31, 2023. The filing details the company's financial performance and operational structure, including its business address at 1 North Waukegan Road, North Chicago, IL 60064. Key financial metrics such as Cost of Goods and Services Sold, Research and Development Expense, and Selling, General and Administrative Expense are referenced, indicating the company's significant operational expenditures.

Why It Matters

This filing provides investors and the public with a comprehensive overview of AbbVie's financial health and strategic direction, crucial for evaluating its future performance and investment potential.

Risk Assessment

Risk Level: medium — The pharmaceutical industry faces inherent risks related to R&D success, regulatory approvals, and competitive pressures, which are reflected in AbbVie's operational expenses.

Key Numbers

• 20231231 — Conformed Period of Report (The fiscal year-end for which the 10-K was filed.)
• 128 — Public Document Count (Number of documents included in the filing.)
• 0001551152 — Central Index Key (CIK) (Unique identifier for AbbVie Inc. with the SEC.)
• 2834 — Standard Industrial Classification (SIC) (Industry code for Pharmaceutical Preparations.)
• 1934 Act — SEC Act (The act under which the 10-K was filed.)

Key Players & Entities

• AbbVie Inc. (company) — Filer of the 10-K
• 001-35565 (company) — SEC File Number for AbbVie Inc.
• 1 North Waukegan Road (company) — Business address of AbbVie Inc.
• North Chicago, IL 60064 (company) — Business address city and zip of AbbVie Inc.
• December 31, 2023 (date) — Conformed period of report end date

FAQ

From the Filing

0001551152-24-000011.txt : 20240220 0001551152-24-000011.hdr.sgml : 20240220 20240220124517 ACCESSION NUMBER: 0001551152-24-000011 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 128 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24652004 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 10-K 1 abbv-20231231.htm 10-K abbv-20231231 0001551152 false 2023 FY http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2023#MoneyMarketFundsMember http://fasb.org/us-gaap/2023#MoneyMarketFundsMember http://fasb.org/us-gaap/2023#OtherNonoperatingInco